An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients With Type 2 Diabetes

This study has been terminated.
(Company decision taken in light of demands by certain national health authorities)
Information provided by:
Sanofi Identifier:
First received: December 18, 2007
Last updated: June 12, 2009
Last verified: June 2009

The purpose of this study is to assess the effect of rimonabant treatment on the histological features of NASH in patients with Type 2 diabetes.

Condition Intervention Phase
Fatty Liver
Drug: rimonabant (SR141716)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of Rimonabant 20 mg Daily for the Treatment of Type 2 Diabetic Patients With Nonalcoholic Steatohepatitis (NASH).

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change in histologic features of NASH from baseline to end of treatment liver biopsy [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Liver fibrosis, AST/ALT, serum hyaluronate [ Time Frame: 18 months ] [ Designated as safety issue: No ]

Enrollment: 89
Study Start Date: February 2008
Study Completion Date: February 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: rimonabant (SR141716)
20 mg daily
Placebo Comparator: 2 Drug: Placebo
daily administration


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with Type 2 diabetes mellitus and a diagnosis of NASH

Exclusion Criteria:

  • Excessive alcohol use
  • Presence of Type 1 diabetes mellitus
  • Other chronic liver disease
  • Previous or current hepatocellular carcinoma
  • Use of medication known to cause steatosis
  • Previous bariatric surgery
  • Pregnancy or breastfeeding
  • Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Please refer to this study by its identifier: NCT00577148

  Show 24 Study Locations
Sponsors and Collaborators
Study Director: ICD CSD Sanofi
  More Information

No publications provided

Responsible Party: ICD, sanofi-aventis Identifier: NCT00577148     History of Changes
Other Study ID Numbers: EFC10144, EudraCT 2007-003013-14
Study First Received: December 18, 2007
Last Updated: June 12, 2009
Health Authority: Mexico: Ministry of Health

Keywords provided by Sanofi:
chronic liver disease

Additional relevant MeSH terms:
Fatty Liver
Liver Diseases
Digestive System Diseases processed this record on April 21, 2014